

WELCOME TO THE THIRD EDITION OF THE REMAP-CAP PANDEMIC NEWSLETTER

THANK YOU

The REMAP-CAP team would like to extend a MASSIVE thank you to EVERYONE for their commitment to the REMAP-CAP study. The UK have now recruited 5000 COVID-19 patients!

Thanks to YOUR hard work, the UK now has:

• 143 (43%) of the 332 sites open globally




 5071 (55%) of the 9182 patients recruited globally



• 5000 (60%) of the 8275 COVID-19 patients recruited globally



VOL3 8th Oct 2021



REMINDERS

- When requesting for access to spinnaker, please remember to send a signed CV, GCP certificate, training log and the delegation log.
- The next WE4YOU seminar 'Vitamin C' is scheduled for Wednesday 3rd November 2021 at 15:00 GMT

Please click the link below to join the webinar:

https://bit.ly/we4youzoom

Webinar ID: 828 8844 2003; Passcode: 632964 Recordings of previous Webinars can be accessed here: https://bit.ly/we4youwebinar

Please only contact
 ukremap-cap@icnarc.org for study
 specific queries and not the database
 team in New Zealand: REMAP-CAP
 (info@remapcap.org) / Spiral Support
 (support@spiral.co.nz)
















Randomised, Embedded, Multi-factorial, Adaptive Platform for Community-Acquired Pneumonia

REMAP-CAP LEAGUE TABLE

Overall top recruiting sites

Top of leader board for overall pandemic patients recruitment is **Russells Hall Hospital** with 183 patients. A special thanks goes to all the sites listed below.















Randomised, Embedded, Multi-factorial, Adaptive Platform for Community-Acquired Pneumonia

ACTIVE PANDEMIC TREATMENT DOMAINS

Active on ICU only

- Vitamin C (REMAP-CAP Ascorbic Acid IMP supplied on request)
- Simvastatin
- Anticoagulation
- ACE-2 / RAS domain (DMX-200 IMP supplied on request)

New Domain

Cysteamine (Cysteamine bitartrate IMP supplied on request)

ACTIVE NON-PANDEMIC TREATMENT DOMAINS

Active on ICU only

- Antibiotics
- Macrolide Duration (only in association with the antibiotic domain)
- Corticosteroid
- Vitamin C

AM028 & AM029

AM028 & AM029 involves: The addition of the Cysteamine domain specific appendix and the Cysteamine intervention We added 1 IMP product to the MHRA CTA: Cysteamine bitartrate. Several study documents have also been updated.

Please note the updated COVID-19 Participant Information Sheets below:

- UK REMAP CAP COVID-19 PeRL ICF V1.8 16.08.2021 (Scotland)
- UK REMAP CAP Perlis ICF (England V1.10, NI V1.9 16.08.2021)
- UK REMAP CAP PIS ICF (Scotland V1.8, NI V1.9, England V1.10 16.08.2021)
- UK REMAP CAP RETRO PIS ICF (Scotland V1.8, NI V1.9 England V1.10 16.08.2021)
- Brief REMAPCAP PIS Summary V3 16.08.2021
- Brief REMAPCAP ProLR_IS Summary V4 16.08.2021

Please note the updated non-pandemic Participant Information Sheets below:

- UK REMAP CAP RETRO PIS ICF RECOVERED CAPACITY V2.6 16.08.2021 (Scotland)
- UK REMAP CAP RETRO PIS ICF V2.6 16.08.2021 (England & NI)
- UK REMAP CAP PIS ICF V2.6 16.08.2021 (Scotland, England, NI)
- UK REMAP CAP PerLR IS ICF ATTORNEY_GUARDIAN_ RELATIVE V2.7 16.08.2021 (Scotland)
- UK REMAP CAP PerLR IS ICF V2.7 16.08.2021 (England & NI)















Randomised, Embedded, Multi-factorial, Adaptive Platform for Community-Acquired Pneumonia







London











Randomised, Embedded, Multi-factorial, Adaptive Platform for **Community-Acquired Pneumonia**

BRITISH MEDICAL JOURNAL AWARDS 2021

The REMAP-CAP team were nominated for the BMJ Critical Care Award. This award recognises teams who have used innovative approaches to deliver safe patient-centred care to critically ill patients. On the 29th September 2021 the REMAP-CAP team were announced winners of this award. We would like to say a special THANK YOU to all the sites that have worked so hard over the past 18 months. We could not have done it without you!



CELEBRATE YOUR SUCCESS

So much has been achieved by the UK REMAP-CAP sites. THANK YOU EVERYONE for your continued SUPPORT. The evidence you are generating is already improving care for patients with COVID-19.

We'd also love to hear from you so please feel free to stay in touch with the REMAP-CAP family via our social media outlets.

We look forward to the time when we can celebrate your success together.



















